Bonus Oct 18, 1999 Nov 05, 1999 Oct 07, 1999 Bonus Ratio: 2 share(s) for every 1 shares held Rights Feb 03, 1995 Mar 02, 1995 May 03, 1995 Rights ratio: 4 share for every 50 held at a price of Rs ...

Revenue 25,774.09 22,753.12 21,763.34 19,159.59 ...

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing developing and marketing wide range of branded and generic formulations and Active ...

Cipla is facing moderate headwinds at the moment. India business underwent a soft two quarters, US business faced supply issues in one main product and Trump tariff pressure has impacted the ...

Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Return on investment - most recent fiscal year 16.16 ...

Cipla's shares are currently priced at Rs 1510.10, reflecting a modest increase of 0.74% today, suggesting investor confidence. Cipla's shares are currently priced at Rs 1507.55, reflecting a daily ...

According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market ...

Formosa and Cipla's agreement grants Cipla exclusive marketing rights for APP13007 in 11 countries, enhancing Cipla's ophthalmology portfolio. APP13007, approved by the FDA in March 2024, provides a ...

This new steroid represents a significant advancement in the ophthalmic market, extending notable patient benefits. "Formosa Pharma welcomes this partnership with Cipla, a well-renowned and respected ...